LF
LFWD.US Lifeward Ltd.
- Market cap
- USD 11.5M
- P/E
- -
- P/B
- 0.94x
- ROE
- -502.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LFWD.US undervalued?
Graham numberThe Graham number of Lifeward Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lifeward Ltd. fundamental analysis
No fundamental analysis for Lifeward Ltd. yet.
Lifeward Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lifeward Ltd.
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabili…
Full company profileLifeward Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lifeward Ltd. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.87M | 7.75M | 6.55M | 4.87M | 4.39M | 5.97M | 5.51M | 13.9M | 25.7M | 22.0M | 21.3M |
| Gross Profit | 736K | 3.10M | 2.83M | 2.73M | 2.19M | 2.90M | 1.91M | 4.45M | 8.22M | 8.43M | 7.38M |
| Operating Income | -30.4M | -22.0M | -19.2M | -14.0M | -12.0M | -12.7M | -19.1M | -23.6M | -19.6M | -16.9M | -27.3M |
| EBITDA | -29.8M | -21.5M | -18.8M | -13.7M | -11.7M | -12.4M | -18.9M | -20.3M | -24.9M | -19.3M | -27.3M |
| Net Income | -32.5M | -24.7M | -21.7M | -15.6M | -13.0M | -12.7M | -19.6M | -22.1M | -28.9M | -19.9M | -36.5M |
| EPS | -5,181 | -2,569 | -1,237 | -227 | -69 | -22 | -26 | -31 | -40 | -1.72 | -9.51 |
| Balance Sheet | |||||||||||
| Total Assets | 31.8M | 22.9M | 15.0M | 24.4M | 28.1M | 94.8M | 74.2M | 63.2M | 30.5M | 22.9M | 30.5M |
| Total Liabilities | 23.5M | 19.2M | 13.0M | 13.6M | 6.29M | 5.37M | 6.07M | 16.7M | 11.6M | 14.5M | 23.3M |
| Shareholders' Equity | 8.26M | 3.71M | 1.95M | 10.8M | 21.8M | 89.4M | 68.2M | 46.5M | 18.8M | 8.41M | 7.27M |
| Cash & Short-term Investments | 23.7M | 14.6M | 9.55M | 16.3M | 20.4M | 88.3M | 67.9M | 28.1M | 6.94M | 2.17M | 4.55M |
| Total Debt | 18.0M | 15.4M | 8.69M | 8.92M | 1.58M | 1.06M | 897K | 1.90M | 880K | 4.39M | 2.47M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -27.5M | -22.5M | -14.8M | -14.8M | -12.6M | -11.5M | -17.9M | -20.7M | -21.7M | -16.8M | -21.4M |
| Capital Expenditure | 452K | 21.0K | 13.0K | 22.0K | 73.0K | 47.0K | 25.0K | 81.0K | 0.00 | 16.0K | 10.7K |
| Free Cash Flow | -28.0M | -22.5M | -14.8M | -14.8M | -12.7M | -11.5M | -17.9M | -20.7M | -21.7M | -16.8M | -21.4M |
| Ratios | |||||||||||
| ROE | -393.5% | -666.8% | -1,114.4% | -144.3% | -59.6% | -14.2% | -28.7% | -47.6% | -153.5% | -236.8% | -502.1% |
| ROA | -102.3% | -108.1% | -144.9% | -63.8% | -46.2% | -13.4% | -26.4% | -35.0% | -94.9% | -87.0% | -119.6% |
| Net Profit Margin | -553.8% | -318.8% | -331.2% | -319.1% | -295.4% | -213.5% | -355.1% | -159.8% | -112.8% | -90.4% | -171.3% |
| Debt to Equity | 2.18x | 4.14x | 4.47x | 0.83x | 0.07x | 0.01x | 0.01x | 0.04x | 0.05x | 0.52x | 0.34x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lifeward Ltd. dividends
Lifeward Ltd. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:12 on Feb 24, 2026.
Who owns Lifeward Ltd.
- Insiders 47.06%
- Institutions 1.37%
- Public & others 51.57%
- Shares outstanding 2.84M
- Free float 1.57M
Top funds holding LFWD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| DFA US Core Equity Class F | 1.16K | 0.04% | 0.00% | Aug 2026 |
| Dimensional US Core Equity 1 ETF | 804.00 | 0.03% | 0.00% | Sep 2026 |
| DFA U.S. Core Equity 1 I | 804.00 | 0.03% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 2 ETF | 97.00 | 0.00% | 0.00% | Oct 2026 |
Top institutions holding LFWD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citadel Advisors Llc | 18.1K | 0.64% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 10.7K | 0.38% | -5.30% | Sep 2026 |
| UBS Group AG | 2.15K | 0.08% | +1.27% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 274.00 | 0.01% | +31.73% | Jun 2026 |
| SBI Securities Co Ltd | 196.00 | 0.01% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 107.00 | 0.00% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 50.00 | 0.00% | 0.00% | Jun 2026 |
| NATIONAL BANK OF CANADA /FI/ | 11.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 4.00 | 0.00% | 0.00% | Jun 2026 |
| Group One Trading, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Lifeward Ltd. company profile
- Company name
- Lifeward Ltd.
- Ticker
- LFWD.US
- ISIN
- IL0011331076
- Exchange
- USA Stocks
- Listed since
- Sep 12, 2014
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 81
- Fiscal year end
- December
- Address
- 3 Hatnufa St., Yokneam Illit, Israel, 2069203
- Phone
- 972 4 959 0123
- Website
- golifeward.com
About Lifeward Ltd.
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals' post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024. Lifeward Ltd. was incorporated in 2001 and is based in Yokneam Illit, Israel.
Lifeward Ltd. management
5- Mr. Joshua HexterInterim Chief Executive Officer · born 1970
- Mr. Ronen Tsimerman CPACFO & Principal Accounting Officer · born 1969
- Ms. Miri ParienteVice President of Operations, Regulatory & Quality · born 1977
- Dr. Keith Dale Rose M.D.Chief Medical Officer · born 1962
- Mr. Craig Peters DPTVice President of Sales - North America